Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

68 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sputum culture reversion in longer treatments with bedaquiline, delamanid, and repurposed drugs for drug-resistant tuberculosis.
Kho S, Seung KJ, Huerga H, Bastard M, Khan PY, Mitnick CD, Rich ML, Islam S, Zhizhilashvili D, Yeghiazaryan L, Nikolenko EN, Zarli K, Adnan S, Salahuddin N, Ahmed S, Vargas ZHR, Bekele A, Shaimerdenova A, Tamirat M, Gelin A, Vilbrun SC, Hewison C, Khan U, Franke M. Kho S, et al. Among authors: rich ml. Nat Commun. 2024 May 9;15(1):3927. doi: 10.1038/s41467-024-48077-8. Nat Commun. 2024. PMID: 38724531 Free PMC article.
Effectiveness of a bedaquiline, linezolid, clofazimine "core" for multidrug-resistant tuberculosis.
Zeng C, Hernán MA, Trevisi L, Sauer S, Mitnick CD, Hewison C, Bastard M, Khan P, Seung KJ, Rich ML, Law S, Kikvidze M, Kirakosyan O, Miankou A, Thit P, Mamsa S, Janmohamed A, Melikyan N, Ahmed S, Vargas D, Binegdie AB, Temirova K, Oyewusi L, Philippe K, Vilbrun SC, Khan U, Huerga H, Franke MF; endTB Observational Study Team. Zeng C, et al. Among authors: rich ml. medRxiv [Preprint]. 2024 Jan 19:2024.01.18.24301453. doi: 10.1101/2024.01.18.24301453. medRxiv. 2024. PMID: 38293100 Free PMC article. Preprint.
Evaluating newly approved drugs in combination regimens for multidrug-resistant tuberculosis with fluoroquinolone resistance (endTB-Q): study protocol for a multi-country randomized controlled trial.
Patil SB, Tamirat M, Khazhidinov K, Ardizzoni E, Atger M, Austin A, Baudin E, Bekhit M, Bektasov S, Berikova E, Bonnet M, Caboclo R, Chaudhry M, Chavan V, Cloez S, Coit J, Coutisson S, Dakenova Z, De Jong BC, Delifer C, Demaisons S, Do JM, Dos Santos Tozzi D, Ducher V, Ferlazzo G, Gouillou M, Khan U, Kunda M, Lachenal N, LaHood AN, Lecca L, Mazmanian M, McIlleron H, Moreau M, Moschioni M, Nahid P, Osso E, Oyewusi L, Panda S, Pâquet A, Thuong Huu P, Pichon L, Rich ML, Rupasinghe P, Salahuddin N, Sanchez Garavito E, Seung KJ, Velásquez GE, Vallet M, Varaine F, Yuya-Septoh FJ, Mitnick CD, Guglielmetti L. Patil SB, et al. Among authors: rich ml. Trials. 2023 Nov 30;24(1):773. doi: 10.1186/s13063-023-07701-6. Trials. 2023. PMID: 38037119 Free PMC article.
Pregnancy and Birth Outcomes in Patients With Multidrug-Resistant Tuberculosis Treated With Regimens That Include New and Repurposed Drugs.
Lotia Farrukh I, Lachenal N, Adenov MM, Ahmed S, Algozhin Y, Coutisson S, Garavito ES, Hewison C, Holtzman D, Huerga H, Janmohamed A, Khan PY, Jacques GL, Lomtadze N, Melikyan N, Mitnick CD, Mussabekova G, Osso E, Perea S, Putri FA, Rashidov M, Rich ML, Sakhabutdinova Y, Seung KJ, Stambekova A, Vásquez DV, Franke MF, Khan U. Lotia Farrukh I, et al. Among authors: rich ml. Clin Infect Dis. 2024 Jan 25;78(1):144-148. doi: 10.1093/cid/ciad445. Clin Infect Dis. 2024. PMID: 37606512 Free PMC article.
Outcomes of WHO-conforming, longer, all-oral multidrug-resistant TB regimens and analysis implications.
Rich ML, Khan U, Zeng C, LaHood A, Franke MF, Atwood S, Bastard M, Burhan E, Danielyan N, Dzhazibekova PM, Gadissa D, Ghafoor A, Hewison C, Islam MS, Kazmi E, Khan PY, Lecca L, Maama LB, Melikyan N, Naing YY, Philippe K, Saki NA, Seung KJ, Skrahina A, Tefera GB, Varaine F, Vilbrun SC, Võ L, Mitnick CD, Huerga H. Rich ML, et al. Int J Tuberc Lung Dis. 2023 Jun 1;27(6):451-457. doi: 10.5588/ijtld.22.0613. Int J Tuberc Lung Dis. 2023. PMID: 37231598 Free PMC article.
Concordance of three approaches for operationalizing outcome definitions for multidrug-resistant TB.
Zeng C, Mitnick CD, Hewison C, Bastard M, Khan P, Seung KJ, Rich ML, Atwood S, Melikyan N, Morchiladze N, Khachatryan N, Khmyz M, Restrepo CG, Salahuddin N, Kazmi E, Dahri AA, Ahmed S, Varaine F, Vilbrun SC, Oyewusi L, Gelin A, Tintaya K, Yeraliyeva LT, Hamid S, Khan U, Huerga H, Franke MF. Zeng C, et al. Among authors: rich ml. Int J Tuberc Lung Dis. 2023 Jan 1;27(1):34-40. doi: 10.5588/ijtld.22.0324. Int J Tuberc Lung Dis. 2023. PMID: 36853128 Free PMC article.
Effectiveness of Bedaquiline Use beyond Six Months in Patients with Multidrug-Resistant Tuberculosis.
Trevisi L, Hernán MA, Mitnick CD, Khan U, Seung KJ, Rich ML, Bastard M, Huerga H, Melikyan N, Atwood SA, Avaliani Z, Llanos F, Manzur-Ul-Alam M, Zarli K, Binegdie AB, Adnan S, Melikyan A, Gelin A, Isani AK, Vetushko D, Daugarina Z, Nkundanyirazo P, Putri FA, Vilbrun C, Khan M, Hewison C, Khan PY, Franke MF. Trevisi L, et al. Among authors: rich ml. Am J Respir Crit Care Med. 2023 Jun 1;207(11):1525-1532. doi: 10.1164/rccm.202211-2125OC. Am J Respir Crit Care Med. 2023. PMID: 36802336 Free PMC article. Clinical Trial.
Corrigendum to 'Culture conversion at six months in patients receiving bedaquiline- and delamanid-containing regimens for the treatment of multidrug-resistant tuberculosis' International Journal of Infectious Diseases Volume 113S1 (2021) S91-S95.
Maretbayeva SM, Rakisheva AS, Adenov MM, Yeraliyeva LT, Algozhin YZ, Stambekova AT, Berikova EA, Yedilbayev A, Rich ML, Seung KJ, Issayeva AM. Maretbayeva SM, et al. Among authors: rich ml. Int J Infect Dis. 2022 Aug;121:105. doi: 10.1016/j.ijid.2022.05.004. Epub 2022 May 23. Int J Infect Dis. 2022. PMID: 35613479 Free article. No abstract available.
68 results